Search research articles
Contact Us
Filters
Showing results (381-390 of 524) with videos related to
Page
of 53
Sort By:
Cell Reports
|
December 3, 2015
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species
Hongliang Zong, Alexander Gozman, Eloisi Caldas-Lopes, et al.
Cancer Cell
|
August 13, 2021
Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis
Kosuke Tanaka, Helena A Yu, Shaoyuan Yang, et al.
The Lancet. Oncology
|
July 1, 2024
Imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial
Salomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors
Leena Gandhi, D Ross Camidge, Moacyr Ribeiro de Oliveira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 29, 2025
Phase I Dose Escalation Trial Combining Olaparib and Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer
Andreas Rimner, Benjamin H Lok, Daphna Y Gelblum, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 9, 2022
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers
Noura J Choudhury, Antonio Marra, Jane S Y Sui, et al.
Plos Genetics
|
June 2, 2012
Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis
Phuoc T Tran, Emelyn H Shroff, Timothy F Burns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2020
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M Rudin, Mark M Awad, Alejandro Navarro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2020
Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer
Sabine Topka, Zoe Steinsnyder, Vignesh Ravichandran, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 2, 2026
Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers
Salomon Tendler, Roberto De Gregorio, Paul Balderes, et al.
Page
of 53
Search research articles
Search
Showing results (381-390 of 524) with videos related to
Sort By:
Page
of 53
Cell Reports
|
December 3, 2015
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species
Hongliang Zong, Alexander Gozman, Eloisi Caldas-Lopes, et al.
Cancer Cell
|
August 13, 2021
Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis
Kosuke Tanaka, Helena A Yu, Shaoyuan Yang, et al.
The Lancet. Oncology
|
July 1, 2024
Imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial
Salomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors
Leena Gandhi, D Ross Camidge, Moacyr Ribeiro de Oliveira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 29, 2025
Phase I Dose Escalation Trial Combining Olaparib and Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer
Andreas Rimner, Benjamin H Lok, Daphna Y Gelblum, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 9, 2022
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers
Noura J Choudhury, Antonio Marra, Jane S Y Sui, et al.
Plos Genetics
|
June 2, 2012
Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis
Phuoc T Tran, Emelyn H Shroff, Timothy F Burns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2020
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M Rudin, Mark M Awad, Alejandro Navarro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2020
Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer
Sabine Topka, Zoe Steinsnyder, Vignesh Ravichandran, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 2, 2026
Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers
Salomon Tendler, Roberto De Gregorio, Paul Balderes, et al.
Page
of 53